Additionally, the expression and function of OATPs changed with the disease progression of NAFLD, and LA, RA, SAA, SAB, SAD, and TSL are potent inhibitors of OATP1 and OATP3 (210, 211). Here, SH3BP5 is linked to metabolic dysfunction-associated steatotic liver disease.